Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL BIOLOGICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL XX SIZE
2.2.1.1. VENDOR POSITIONING GRID
2.2.1.2. TECHNOLOGY LIFE LINE CURVE
2.2.1.3. TRIPOD DATA VALIDATION MODEL
2.2.1.4. MARKET GUIDE
2.2.1.5. MULTIVARIATE MODELLING
2.2.1.6. TOP TO BOTTOM ANALYSIS
2.2.1.7. CHALLENGE MATRIX
2.2.1.8. APPLICATION COVERAGE GRID
2.2.1.9. STANDARDS OF MEASUREMENT
2.2.1.10. VENDOR SHARE ANALYSIS
2.2.1.11. DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.1.12. DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL BIOLOGICS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
5 INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1.1. PATENT LANDSCAPE
5.1.1.2. USPTO NUMBER
5.1.1.3. PATENT EXPIRY
5.1.1.4. EPIO NUMBER
5.1.1.5. PATENT STRENGTH AND QUALITY
5.1.1.6. PATENT CLAIMS
5.1.1.7. PATENT CITATIONS
5.1.1.8. PATENT LITIGATION AND LICENSING
5.1.1.9. FILE OF PATENT
5.1.1.10. PATENT RECEIVED CONTRIES
5.1.1.11. TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6 EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7 MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8 REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR BIOLOGICS
Company Name Therapeutic Area
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved But Not Yest Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR GLOBAL BIOLOGICS MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
10 MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1.1. BRAND NAME
10.1.1.2. GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.1 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1.1. FORECAST MARKET OUTLOOK
10.13.1.2. CROSS COMPETITION
10.13.1.3. THERAPEUTIC PORTFOLIO
10.13.1.4. CURRENT DEVELOPMENT SCENARIO
11 MARKET ACCESS
11.1 10-YEAR MARKET FORECAST
11.2 CLINICAL TRIAL RECENT UPDATES
11.3 ANNUAL NEW FDA APPROVED DRUGS
11.4 DRUGS MANUFACTURER AND DEALS
11.5 MAJOR DRUG UPTAKE
11.6 CURRENT TREATMENT PRACTICES
11.7 IMPACT OF UPCOMING THERAPY
12 MARKET OVERVIEW
12.1 DRIVERS
12.2 RESTRAINTS
12.3 OPPORTUNITIES
12.4 CHALLENGES
13 GLOBAL BIOLOGICS MARKET, BY TYPE
13.1 OVERVIEW
13.2 TUMOR NECROSIS FACTOR-A (TNF) INHIBITORS
13.2.1.1. BY TYPE
13.2.1.2. ADALIMUMAB
13.2.1.3. CERTOLIZUMAB PEGOL
13.2.1.4. ETANERCEPT
13.2.1.5. INFLIXIMAB
13.2.1.6. GOLIMUMAB
13.2.1.7. OTHERS
13.2.1.8. BY ROUTE OF ADMINISTRATION
13.2.1.9. INJECTION
13.2.1.10. INFUSION
13.2.1.11. OTHERS
13.2.1.12. BY SOURCE MATERIAL
13.2.1.13. MICROBIAL
13.2.1.14. MAMMALIAN
13.2.1.15. OTHERS
13.3 B-CELL INHIBITORS
13.3.1.1. BY TYPE
13.3.1.2. RITUXIMAB
13.3.1.3. OTHERS
13.3.1.4. BY ROUTE OF ADMINISTRATION
13.3.1.5. INJECTION
13.3.1.6. INFUSION
13.3.1.7. OTHERS
13.3.1.8. BY SOURCE MATERIAL
13.3.1.9. MICROBIAL
13.3.1.10. MAMMALIAN
13.3.1.11. OTHERS
13.4 INTERLEUKIN INHIBITORS
13.4.1.1. BY TYPE
13.4.1.2. ANAKINRA
13.4.1.3. CANAKINUMAB
13.4.1.4. RILONACEPT
13.4.1.5. SECUKINUMAB
13.4.1.6. IXEKIZUMAB
13.4.1.7. TOCILIZUMAB
13.4.1.8. SARILUMAB
13.4.1.9. OTHERS
13.4.1.10. BY ROUTE OF ADMINISTRATION
13.4.1.11. INJECTION
13.4.1.12. INFUSION
13.4.1.13. OTHERS
13.4.1.14. BY SOURCE MATERIAL
13.4.1.15. MICROBIAL
13.4.1.16. MAMMALIAN
13.4.1.17. OTHERS
13.5 T-CELL INHIBITORS (ABATACEPT)
13.6 OTHERS
14 GLOBAL BIOLOGICS MARKET, BY DRUG CLASSIFICATION
14.1 OVERVIEW
14.2 BRANDED DRUGS
14.2.1.1. HUMIRA
14.2.1.2. RITUXAN
14.2.1.3. ENBREL
14.2.1.4. HERCEPTIN
14.2.1.5. AVASTIN
14.2.1.6. REMICADE
14.2.1.7. NEULASTA
14.2.1.8. AVONEX
14.2.1.9. LUCENTIS
14.2.1.10. ORENCIA
14.2.1.11. EYLEA
14.2.1.12. SIMULECT
14.2.1.13. OTHERS
14.3 GENERIC DRUGS
15 GLOBAL BIOLOGICS MARKET, BY DRUG CLASS
15.1 OVERVIEW
15.2 MONOCLONAL ANTIBODIES (MABS)
15.2.1.1. ANTI-CANCER MABS
15.2.1.2. IMMUNOLOGICAL MABS
15.2.1.3. ANTI-INFECTIVE MONOCLONAL ANTIBODIES (MABS)
15.2.1.4. CARDIOVASCULAR AND CEREBROVASCULAR MABS
15.2.1.5. NEUROPHARMACOLOGICAL MABS
15.2.1.6. OTHERS MABS
15.3 THERAPEUTIC PROTEINS
15.3.1.1. METABOLIC DISORDERS THERAPEUTIC PROTEINS
15.3.1.2. CANCER THERAPEUTIC PROTEINS
15.3.1.3. CARDIOVASCULAR THERAPEUTIC PROTEINS
15.3.1.4. IMMUNOLOGICAL THERAPEUTIC PROTEINS
15.3.1.5. OTHERS THERAPEUTIC PROTEINS
15.4 VACCINES
15.4.1.1. ANTI-INFECTIVE VACCINES
15.4.1.2. AUTOIMMUNITY VACCINES
15.4.1.3. OTHERS
15.5 CELLULAR BASED BIOLOGICS
15.6 RECOMBINANT INSULIN
15.7 GENE BASED BIOLOGICS
15.8 OTHER PRODUCTS
16 GLOBAL BIOLOGICS MARKET, BY ROUTE OF ADMINISTRATION
16.1 OVERVIEW
16.2 INJECTION
16.3 INFUSION
16.4 OTHERS
17 GLOBAL BIOLOGICS MARKET, BY APPLICATION
17.1 OVERVIEW
17.2 ONCOLOGY
17.2.1.1. BREAST CANCER
17.2.1.2. LEUKEMIA
17.2.1.3. OVARIAN CANCER
17.2.1.4. NON-HODGKIN LYMPHOMA
17.2.1.5. PROSTATE CANCER
17.2.1.6. COLORECTAL CANCER
17.2.1.7. OTHERS
17.2.1.8. BLADDER CANCER
17.2.1.9. LUNG CANCER
17.2.1.10. OTHERS
17.3 AUTOIMMUNE DISEASES
17.3.1.1. SYSTEMIC SCLEROSIS
17.3.1.2. CROHN’S DISEASE
17.3.1.3. RHEUMATOID ARTHRITIS
17.3.1.4. SYSTEMIC LUPUS ERYTHEMATOUS
17.3.1.5. OTHERS
17.3.1.6. SJOGREN'S SYNDROME
17.3.1.7. MULTIPLE SCLEROSIS
17.3.1.8. PERNICIOUS ANEMIA
17.3.1.9. OTHERS
17.4 DIABETES
17.5 INFECTIOUS DISEASES
17.6 CARDIOVASCULAR DISEASES
17.7 OPHTHALMIC CONDITIONS
17.8 DERMATOLOGICAL DISEASES
17.9 OTHERS
18 GLOBAL BIOLOGICS MARKET, BY SOURCE MATERIAL
18.1 OVERVIEW
18.2 MICROBIAL
18.3 MAMMALIAN
18.4 OTHERS
19 GLOBAL BIOLOGICS MARKET, BY END USER
19.1 OVERVIEW
19.2 HOSPITALS
19.2.1.1. ACUTE CARE HOSPITALS
19.2.1.2. LONG-TERM CARE HOSPITALS
19.2.1.3. NURSING FACILITIES
19.2.1.4. REHABILITATION CENTERS
19.3 SPECIALTY CLINICS
19.4 AMBULATORY SURGICAL CENTERS
19.5 OTHERS
20 GLOBAL BIOLOGICS MARKET, BY DISTRIBUTION CHANNEL
20.1 OVERVIEW
20.2 DIRECT TENDER
20.3 RETAIL SALES
20.3.1.1. HOSPITAL PHARMACIES
20.3.1.2. RETAIL PHARMACIES
20.3.1.3. ONLINE PHARMACIES
20.4 OTHERS (IF ANY)
21 GLOBAL BIOLOGICS MARKET, SWOT AND DBMR ANALYSIS
22 GLOBAL BIOLOGICS MARKET, COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: GLOBAL
22.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
22.3 COMPANY SHARE ANALYSIS: EUROPE
22.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
22.5 MERGERS & ACQUISITIONS
22.6 NEW PRODUCT DEVELOPMENT & APPROVALS
22.7 EXPANSIONS
22.8 REGULATORY CHANGES
22.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
23 GLOBAL BIOLOGICS MARKET, BY REGION
23.1 GLOBAL BIOLOGICS MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
23.2 NORTH AMERICA
23.2.1.1. U.S.
23.2.1.2. CANADA
23.2.1.3. MEXICO
23.3 EUROPE
23.3.1.1. GERMANY
23.3.1.2. U.K.
23.3.1.3. ITALY
23.3.1.4. FRANCE
23.3.1.5. SPAIN
23.3.1.6. RUSSIA
23.3.1.7. SWITZERLAND
23.3.1.8. TURKEY
23.3.1.9. BELGIUM
23.3.1.10. NETHERLANDS
23.3.1.11. DENMARK
23.3.1.12. SWEDEN
23.3.1.13. POLAND
23.3.1.14. NORWAY
23.3.1.15. FINLAND
23.3.1.16. REST OF EUROPE
23.4 ASIA-PACIFIC
23.4.1.1. JAPAN
23.4.1.2. CHINA
23.4.1.3. SOUTH KOREA
23.4.1.4. INDIA
23.4.1.5. SINGAPORE
23.4.1.6. THAILAND
23.4.1.7. INDONESIA
23.4.1.8. MALAYSIA
23.4.1.9. PHILIPPINES
23.4.1.10. AUSTRALIA
23.4.1.11. NEW ZEALAND
23.4.1.12. VIETNAM
23.4.1.13. TAIWAN
23.4.1.14. REST OF ASIA-PACIFIC
23.5 SOUTH AMERICA
23.5.1.1. BRAZIL
23.5.1.2. ARGENTINA
23.5.1.3. REST OF SOUTH AMERICA
23.6 MIDDLE EAST AND AFRICA
23.6.1.1. SOUTH AFRICA
23.6.1.2. EGYPT
23.6.1.3. BAHRAIN
23.6.1.4. UNITED ARAB EMIRATES
23.6.1.5. KUWAIT
23.6.1.6. OMAN
23.6.1.7. QATAR
23.6.1.8. SAUDI ARABIA
23.6.1.9. REST OF MEA
23.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
24 GLOBAL BIOLOGICS MARKET, COMPANY PROFILE
24.1 BRISTOL-MYERS SQUIBB COMPANY
24.1.1.1. COMPANY OVERVIEW
24.1.1.2. REVENUE ANALYSIS
24.1.1.3. GEOGRAPHIC PRESENCE
24.1.1.4. PRODUCT PORTFOLIO
24.1.1.5. RECENT DEVELOPMENTS
24.2 ABBVIE
24.2.1.1. COMPANY OVERVIEW
24.2.1.2. REVENUE ANALYSIS
24.2.1.3. GEOGRAPHIC PRESENCE
24.2.1.4. PRODUCT PORTFOLIO
24.2.1.5. RECENT DEVELOPMENTS
24.3 AMGEN INC.
24.3.1.1. COMPANY OVERVIEW
24.3.1.2. REVENUE ANALYSIS
24.3.1.3. GEOGRAPHIC PRESENCE
24.3.1.4. PRODUCT PORTFOLIO
24.3.1.5. RECENT DEVELOPMENTS
24.4 GENENTECH USA, INC. (PARENT COMPANY F. HOFFMANN-LA ROCHE AG)
24.4.1.1. COMPANY OVERVIEW
24.4.1.2. REVENUE ANALYSIS
24.4.1.3. GEOGRAPHIC PRESENCE
24.4.1.4. PRODUCT PORTFOLIO
24.4.1.5. RECENT DEVELOPMENTS
24.5 BAYER AG
24.5.1.1. COMPANY OVERVIEW
24.5.1.2. REVENUE ANALYSIS
24.5.1.3. GEOGRAPHIC PRESENCE
24.5.1.4. PRODUCT PORTFOLIO
24.5.1.5. RECENT DEVELOPMENTS
24.6 SANOFI
24.6.1.1. COMPANY OVERVIEW
24.6.1.2. REVENUE ANALYSIS
24.6.1.3. GEOGRAPHIC PRESENCE
24.6.1.4. PRODUCT PORTFOLIO
24.6.1.5. RECENT DEVELOPMENTS
24.7 BIOGEN
24.7.1.1. COMPANY OVERVIEW
24.7.1.2. REVENUE ANALYSIS
24.7.1.3. GEOGRAPHIC PRESENCE
24.7.1.4. PRODUCT PORTFOLIO
24.7.1.5. RECENT DEVELOPMENTS
24.8 CLINIGEN, INC.
24.8.1.1. COMPANY OVERVIEW
24.8.1.2. REVENUE ANALYSIS
24.8.1.3. GEOGRAPHIC PRESENCE
24.8.1.4. PRODUCT PORTFOLIO
24.8.1.5. RECENT DEVELOPMENTS
24.9 NOVARTIS AG
24.9.1.1. COMPANY OVERVIEW
24.9.1.2. REVENUE ANALYSIS
24.9.1.3. GEOGRAPHIC PRESENCE
24.9.1.4. PRODUCT PORTFOLIO
24.9.1.5. RECENT DEVELOPMENTS
24.1 GSK
24.10.1.1. COMPANY OVERVIEW
24.10.1.2. REVENUE ANALYSIS
24.10.1.3. GEOGRAPHIC PRESENCE
24.10.1.4. PRODUCT PORTFOLIO
24.10.1.5. RECENT DEVELOPMENTS
24.11 SEAGEN INC.
24.11.1.1. COMPANY OVERVIEW
24.11.1.2. REVENUE ANALYSIS
24.11.1.3. GEOGRAPHIC PRESENCE
24.11.1.4. PRODUCT PORTFOLIO
24.11.1.5. RECENT DEVELOPMENTS
24.12 LILLY
24.12.1.1. COMPANY OVERVIEW
24.12.1.2. REVENUE ANALYSIS
24.12.1.3. GEOGRAPHIC PRESENCE
24.12.1.4. PRODUCT PORTFOLIO
24.12.1.5. RECENT DEVELOPMENTS
24.13 JANSSEN BIOTECH, INC. (SUBSIDIARY OF JOHNSON & JOHNSON)
24.13.1.1. COMPANY OVERVIEW
24.13.1.2. REVENUE ANALYSIS
24.13.1.3. GEOGRAPHIC PRESENCE
24.13.1.4. PRODUCT PORTFOLIO
24.13.1.5. RECENT DEVELOPMENTS
24.14 TEVA PHARMACEUTICAL INDUSTRIES LTD.
24.14.1.1. COMPANY OVERVIEW
24.14.1.2. REVENUE ANALYSIS
24.14.1.3. GEOGRAPHIC PRESENCE
24.14.1.4. PRODUCT PORTFOLIO
24.14.1.5. RECENT DEVELOPMENTS
24.15 TAKEDA PHARMACEUTICAL COMPANY LIMITED.
24.15.1.1. COMPANY OVERVIEW
24.15.1.2. REVENUE ANALYSIS
24.15.1.3. GEOGRAPHIC PRESENCE
24.15.1.4. PRODUCT PORTFOLIO
24.15.1.5. RECENT DEVELOPMENTS
24.16 UNITED THERAPEUTICS CORPORATION.
24.16.1.1. COMPANY OVERVIEW
24.16.1.2. REVENUE ANALYSIS
24.16.1.3. GEOGRAPHIC PRESENCE
24.16.1.4. PRODUCT PORTFOLIO
24.16.1.5. RECENT DEVELOPMENTS
24.17 MERCK & CO., INC.
24.17.1.1. COMPANY OVERVIEW
24.17.1.2. REVENUE ANALYSIS
24.17.1.3. GEOGRAPHIC PRESENCE
24.17.1.4. PRODUCT PORTFOLIO
24.17.1.5. RECENT DEVELOPMENTS
24.18 ASTRAZENECA
24.18.1.1. COMPANY OVERVIEW
24.18.1.2. REVENUE ANALYSIS
24.18.1.3. GEOGRAPHIC PRESENCE
24.18.1.4. PRODUCT PORTFOLIO
24.18.1.5. RECENT DEVELOPMENTS
24.19 CELLTRION HEALTHCARE CO.,LTD.
24.19.1.1. COMPANY OVERVIEW
24.19.1.2. REVENUE ANALYSIS
24.19.1.3. GEOGRAPHIC PRESENCE
24.19.1.4. PRODUCT PORTFOLIO
24.19.1.5. RECENT DEVELOPMENTS
24.2 SUN PHARMACEUTICAL INDUSTRIES, INC.
24.20.1.1. COMPANY OVERVIEW
24.20.1.2. REVENUE ANALYSIS
24.20.1.3. GEOGRAPHIC PRESENCE
24.20.1.4. PRODUCT PORTFOLIO
24.20.1.5. RECENT DEVELOPMENTS
24.21 HIKMA PHARMACEUTICALS PLC
24.21.1.1. COMPANY OVERVIEW
24.21.1.2. REVENUE ANALYSIS
24.21.1.3. GEOGRAPHIC PRESENCE
24.21.1.4. PRODUCT PORTFOLIO
24.21.1.5. RECENT DEVELOPMENTS
24.22 LEO PHARMA A/S
24.22.1.1. COMPANY OVERVIEW
24.22.1.2. REVENUE ANALYSIS
24.22.1.3. GEOGRAPHIC PRESENCE
24.22.1.4. PRODUCT PORTFOLIO
24.22.1.5. RECENT DEVELOPMENTS
24.23 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.
24.23.1.1. COMPANY OVERVIEW
24.23.1.2. REVENUE ANALYSIS
24.23.1.3. GEOGRAPHIC PRESENCE
24.23.1.4. PRODUCT PORTFOLIO
24.23.1.5. RECENT DEVELOPMENTS
24.24 BIOCON BIOLOGICS LIMITED (A SUBSIDIARY OF BIOCON LIMITED)
24.24.1.1. COMPANY OVERVIEW
24.24.1.2. REVENUE ANALYSIS
24.24.1.3. GEOGRAPHIC PRESENCE
24.24.1.4. PRODUCT PORTFOLIO
24.24.1.5. RECENT DEVELOPMENTS
25 RELATED REPORTS
26 CONCLUSION
27 QUESTIONNAIRE
28 ABOUT DATA BRIDGE MARKET RESEARCH
